Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock

• Published in: JACC. Heart failure Vol. 11; no. 10; pp. 1337 - 1347
• Main Authors: Berg-Hansen, Kristoffer, Christensen, Kristian Hylleberg, Gopalasingam, Nigopan, Nielsen, Roni, Eiskjær, Hans, Møller, Niels, Birkelund, Thomas, Christensen, Steffen, Wiggers, Henrik
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.10.2023
• Subjects: 3-hydroxybutyrate; cardiac output; cardiogenic shock; invasive hemodynamics; ketone ester; metabolism; SVO2; VIS; CrSO2; CPO; invasive hemodynamics; 3-hydroxybutyrate; LVEF; PrSO2; cardiogenic shock; 3-OHB; CO; cardiac output; CS; ketone ester; metabolism; KE
• ISSN: 2213-1779
• DOI: 10.1016/j.jchf.2023.05.029

Cardiogenic shock (CS) is a life-threatening condition with sparse treatment options. The ketone body 3-hydroxybutyrate has favorable hemodynamic effects in patients with stable chronic heart failure. Yet, the hemodynamic effects of exogenous ketone ester (KE) in patients with CS remain unknown. The authors aimed to assess the hemodynamic effects of single-dose enteral treatment with KE in patients with CS. In a double-blind, crossover study, 12 patients with CS were randomized to an enteral bolus of KE and isocaloric, isovolumic placebo containing maltodextrin. Patients were assessed with pulmonary artery catheterization, arterial blood samples, echocardiography, and near-infrared spectroscopy for 3 hours following each intervention separated by a 3-hour washout period. KE increased circulating 3-hydroxybutyrate (2.9 ± 0.3 mmol/L vs 0.2 ± 0.3 mmol/L, P < 0.001) and was associated with augmented cardiac output (area under the curve of relative change: 61 ± 22 L vs 1 ± 18 L, P = 0.044). Also, KE increased cardiac power output (0.07 W [95% CI: 0.01-0.14]; P = 0.037), mixed venous saturation (3 percentage points [95% CI: 1-5 percentage points]; P = 0.010), and forearm perfusion (3 percentage points [95% CI: 0-6 percentage points]; P = 0.026). Right (P = 0.048) and left (P = 0.017) ventricular filling pressures were reduced whereas heart rate and mean arterial and pulmonary arterial pressures remained similar. Left ventricular ejection fraction improved by 4 percentage points (95% CI: 2-6 percentage points; P = 0.005). Glucose levels decreased by 2.6 mmol/L (95% CI: −5.2 to 0.0; P = 0.047) whereas insulin levels remained unaltered. Treatment with KE improved cardiac output, biventricular function, tissue oxygenation, and glycemic control in patients with CS (Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock [KETO-SHOCK1]; NCT04642768) [Display omitted]